Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Type 1 Diabetes
Key Patent Awarded for DiaKine Therapeutics' Anti-Inflammatory Drugs
January 25th, 2008
Drugs under development by DiaKine Therapeutics to potentially cure diabetes and reverse its complications have been granted a U.S. patent, the company announced at the 26th Annual J.P. Morgan Healthcare Conference in San Francisco. Patent number 7,247,630 covers novel tricyclic compounds that regulate cytokines. Cytokines may mistakenly attack normal organs and tissue and cause diseases such as diabetes and related complications such as kidney and eye disease. "These drugs were designed to prevent or treat diseases, such as type 1 diabetes and multiple sclerosis, that are affected by intracellular cytokine signaling," said Dr. Jerry Nadler, DiaKine's Chief Scientific...
Source: Medical Patent Business Week (2008-01-25)
|
